BIA
NBIX icon

Bell Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Bell Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.91K Sell
41
-26
-39% -$3.86K ﹤0.01% 845
2026
Q1 		$8.83K Buy
67
+29
+76% +$3.85K ﹤0.01% 726
2025
Q4 		$5.39K Sell
38
-4
-10% -$579 ﹤0.01% 942
2025
Q3 		$5.9K Sell
42
-5
-11% -$677 ﹤0.01% 845
2025
Q2 		$5.91K Buy
47
+17
+57% +$1.95K ﹤0.01% 910
2025
Q1 		$3.32K Hold
30
– – ﹤0.01% 1099
2024
Q4 		$4.09K Buy
30
+9
+43% +$1.11K ﹤0.01% 1015
2024
Q3 		$2.42K Hold
21
– – ﹤0.01% 1270
2024
Q2 		$2.89K Hold
21
– – ﹤0.01% 1196
2024
Q1 		$2.9K Hold
21
– – ﹤0.01% 1189
2023
Q4 		$2.77K Sell
21
-9
-30% -$1.04K ﹤0.01% 1191
2023
Q3 		$3.38K Sell
30
-4
-12% -$421 ﹤0.01% 1013
2023
Q2 		$3.21K Sell
34
-5
-13% -$489 ﹤0.01% 1052
2023
Q1 		$3.95K Buy
39
+5
+15% +$520 ﹤0.01% 892
2022
Q4 		$4.06K Buy
34
+4
+13% +$469 ﹤0.01% 916
2022
Q3 		$3K Hold
30
– – ﹤0.01% 949
2022
Q2 		$3K Buy
+30
New +$2.77K ﹤0.01% 978
2021
Q4 		– Sell
-19
Closed -$2K – 1892
2021
Q3 		$2K Buy
+19
New +$1.79K ﹤0.01% 1110

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bell Investment Advisors's NBIX Position: Q2 2026 in Review

Bell Investment Advisors reduced its Neurocrine Biosciences (NBIX) stake by 39% in Q2 2026, selling an estimated $3.86K and leaving 41 shares worth $6.91K. The position accounts for ﹤0.01% of the portfolio, ranked #845.

Bell Investment Advisors first reported a position in NBIX in Q3 2021 and has held it in 18 quarters since. The position peaked at $8.83K in Q1 2026. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bell Investment Advisors held 41 shares of Neurocrine Biosciences worth $6.91K as of Q2 2026.
  • Bell Investment Advisors sold 26 Neurocrine Biosciences shares in Q2 2026, an estimated $3.86K.
  • Neurocrine Biosciences made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #845 holding.
  • Bell Investment Advisors first reported a position in Neurocrine Biosciences in Q3 2021 and has held it in 18 quarters since.
  • Bell Investment Advisors's Neurocrine Biosciences position peaked at $8.83K in Q1 2026.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.